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Association of IL10, IL10RA, and IL10RB Polymorphisms with 
Benign Prostate Hyperplasia in Korean Population
Cytokines such as interleukin 10 (IL10) may play an important role in the process of 
inflammation. The aim of this study was to analyze the association between IL10, IL10RA 
and IL10RB single nucleotide polymorphisms (SNPs), and benign prostate hyperplasia (BPH) 
in Korean population. All patients with BPH were divided into two groups according to 
international porostate symptom score (IPSS), prostate specific antigen (PSA) level, Qmax, 
and prostate volume. We selected two IL10 SNPs (rs1518111 and rs1554286), three IL10RA 
SNPs (rs2256111, rs4252243, and rs2228054), and two IL10RB SNPs (rs999788 and 
rs2834167). Genotypes of seven SNPs were determined through direct sequencing. The G/
G genotype of IL10RB polymorphism (rs2834167) was associated with a high PSA level 
compared with the A/G + A/A genotypes (P = 0.009). Of IL10 SNP, the A/A genotype of 
rs1518111 and T/T genotype of rs1554286 were associated with small prostate volume, 
respectively (P = 0.011, P = 0.014). Moreover, the T/T genotype of IL10RB polymorphism 
(rs999788) was associated with high prostatic volume compared with the T/C + C/C 
genotypes (P = 0.033). The linkage disequilibrium (LD) blocks were formed in IL10 and 
IL10RA. However, haplotypes in the LD block were not associated with BPH. It is concluded 
that there is a strong association between the IL10 and IL10RB SNPs, and BPH in Korean 
population. 
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INTRODUCTION
Benign prostatic hyperplasia (BPH) is a common disease and 
occurs in about one third of men in their sixties. In Korea, the 
overall prevalence of BPH was 40%, and this result suggests an 
increasing tendency of BPH prevalence (1). BPH is a complex 
disease from multiple etiologies and pathogenesis point of view. 
Recently, several reports revealed that BPH is related with im-
mune-mediated inflammatory response (2, 3). Experimental 
investigations using prostatitis in mice and rats suggested auto-
immune responses and genetic background as etiologic factors 
(4). Chronic inflammation has been documented for years in 
BPH, and it becomes evident as a major factor in disease initia-
tion and progression (5). 
  Cytokines such as interleukin 10 (IL10) and interleukin 2 (IL2) 
have been found in prostate secretion fluids of chronic prostati-
tis (6). These cytokines maybe play an important role in the pro-
cess of inflammation. IL10, which is anti-inflammatory cytokine 
opposing the inflammatory reaction, leads to increase levels of 
the regulatory cytokine (IL2) (6). IL10 is produced primarily by 
monocytes and to a lesser extent by lymphocytes. IL10 is capa-
ble of inhibiting synthesis of pro-inflammatory cytokines such 
as IL2, interleukin 3, tumor necrosis factor alpha and interferon 
alpha made by macrophages and type 1 T helper cells. The IL10 
gene is located in chromosome 1 and consists of five exons. IL10 
has been shown to interact with interleukin 10 receptor, alpha 
(IL10RA) and IL10 receptor, beta (IL10RB).
  Single nucleotide polymorphism (SNP) may regulate the bio-
synthesis, activations, and inactivation of genes and could in-
fluence the pathogenesis of disease initiation and progression. 
Genetic strategy such as polymorphism has been used to inves-
tigate pathogenesis of BPH. Several polymorphisms have been 
reported to have positive associations with prostatic growth (7). 
The aim of this study was to analyze the association between 
IL10, IL10RA and IL10RB SNPs, and BPH in Korean population.
 
MATERIALS AND METHODS
Study population
The present study consisted of 233 patients with BPH and 214 
age-matched normal healthy patients. The patients with BPH 
were enrolled from Kyung Hee University Hospital between 
January 2002 and December 2008. All healthy control patients 
underwent screening and had a normal serum prostate-specif-
ic antigen (PSA) level (< 4 ng/mL). The patient with BPH com-
plained of moderate or severe lower urinary tract symptoms.Yoo KH, et al.  •  Polymorphism of IL10, IL10RA, and IL10RB in Benign Prostatic Hyperplasia
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PCR products were amplified using internal forward and reverse 
primers and a PRISM BigDye Terminator v3.1 Cycle sequenc-
ing Kit. The DNA samples containing extension products were 
added to Hi-Di formamide (Applied Biosystems, Foster City, CA, 
USA). The mixture was incubated at 95°C for 5 min, followed by 
5 min on ice, and then analyzed by the ABI Prism 3730XL DNA 
analyzer (Applied Biosystems). Sequence data were analyzed 
using SeqManII software (v2.3; DNAATAR Inc., Madison, WI, 
USA).
Statistical analysis
We analyzed genetic data in control and BPH subjects. SNPStats 
(http://bioinfo.iconcologia.net/index.php), HelixTree (Golden 
Helix Inc., MT, USA), and SNPAnalyzer (ISTECH Inc., Goyang, 
Korea) software were used to analyze genetic data. The Hardy-
Weinberg equilibrium (HWE) was assessed by SNPStats in con-
trol and BPH cases. Multiple logistic regression models (codom-
inant, dominant and recessive model) were used to calculate 
odds ratio (OR), 95% confidence interval (CI), and correspond-
ing P values with Bonferroni correction, while controlling for 
age as a covariable (10). A linkage disequilibrium (LD) block of 
polymorphisms was tested using Haploview version 4.02 (11). 
A P < 0.05 was considered significant.
Ethics statement
The institutional review board at Kyung Hee University Hospital 
approved this study (KMC IRB 0913-03). All patients with BPH 
provided informed consent for the use of their clinical data and 
samples. 
RESULTS
The clinical characteristics of the study subject with BPH at base-
line were given in Table 2. The median age of the BPH subjects 
was 66.0 yr. A total of 233 BPH subjects and 214 age-matched 
control subjects were genotyped to analyze associations between 
SNPs and BPH. 
Fig. 1. Gene map and single nucleotide polymorphisms in the IL10 (A), IL10RA (B), 
and IL10RB (C) genes. Exons are marked with black boxes, and 5´-untranslated regions 
are marked with white boxes. The first nucleotide is denoted as + 1. Arrows indicate 
the location of each SNP.
rs1518111
rs4252243
rs999788
rs2834167
rs2256111
rs2228054
rs1554286
5´
5´
5´
3´
3´
3´
A
B
C
Table 1. Primer sequences of seven polymorphisms
Gene symbol SNP Sequence (5´-3´) Size (bp)
IL10 rs1554286 Forward
Reverse
CCAATCTCTCACTCACCTTTGG
TGCTCAAAGAGAAATGAGCAAG
359 
IL10 rs1518111 Forward
Reverse
CCAAACCTCAAGTTCATTCTCC
GAGCCAAAGGTGAGTGAGAGAT
385
IL10RA rs4252243 Forward
Reverse
CAGCAAACAATTCCACTCTTCA
GCCTTACGCACGTTTATTTACC
373
IL10RA rs2256111 Forward
Reverse
GCCCTCAAGTCTCATGGTATTC
GGTGGTTTCTACTCCCTCCTCT
368
IL10RA rs2228054 Forward
Reverse
CCCCAACTCCATTTAGTGACTC
GGTGGTTTCTACTCCCTCCTCT
339
IL10RB rs999788 Forward
Reverse
TCTATGGCTGTGAGTGTGTGTG
GCTGTCCAGTGTCTTGGGTAAT
319
IL10RB rs2834167 Forward
Reverse
GGGCTTTTTCATGGGCATCTGT
CAAATCGTCAACCATCACAACT
404
Sample processing
Lower urinary tract symptoms were quantified using interna-
tional prostate symptom score (IPSS). Uroflowmetry was done 
to measure peak urinary flow rate (Qmax) for all patients. Serum 
PSA levels were checked in all BPH patients. The patients with a 
serum PSA level more than 4 ng/mL underwent transrectal ul-
trasound-guided prostate biopsy to rule out prostate cancer. 
Prostate size was assessed with transrectal ultrasound. Exclu-
sion criteria for this study were prostate cancer, neurogenic blad-
der, urinary tract infection, uncontrolled diabetes mellitus, and 
cardiovascular disease. All patients with BPH were divided into 
two groups according to several multicenter studies; low (0-19) 
and high (≥ 20) IPSS group, low (< 1.5 ng/mL) and high (≥ 1.5 ng/ 
mL) PSA level, low (< 10 mL/sec) and high (≥ 10 mL/sec) Qmax, 
and small (< 30 mL) and large (≥ 30 mL) prostate volume (8, 9). 
Genomic DNA was extracted from blood samples collected in 
EDTA using the Qiagen DNA Extraction kit (Qiagen, Tokyo, Ja-
pan).
SNP selection
We selected two IL10 SNPs (rs1518111 and rs1554286), three 
IL10RA SNPs (rs2256111, rs4252243, and rs2228054), and two 
IL10RB SNPs (rs999788 and rs2834167) with greater than 0.3 
heterozygosity among SNPs located in the exon and promoter 
region (http://www.ncbi.nlm.nih.gov/SNP, BUILD 130) for anal-
ysis (Fig. 1). 
Direct sequencing
Genotypes of two IL10 SNPs (rs1518111 and rs1554286), three 
IL10RA SNPs (rs2256111, rs4252243, and rs2228054), and two 
IL10RB SNPs (rs999788 and rs2834167) were determined through 
direct sequencing. Genomic DNA was amplified using PCR 
primers (Table 1). PCR consisted of 35 cycles at 94°C for 30 sec, 
58°C for 30 sec, 72°C for 1 min, and 1 cycle at 72°C for 7 min to 
terminate the reaction. For automated direct sequencing, the Yoo KH, et al.  •  Polymorphism of IL10, IL10RA, and IL10RB in Benign Prostatic Hyperplasia
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  Genotype distributions of SNPs in this study were in Hardy-
Weinberg equilibrium in control subjects (IL10 SNPs [rs1518111, 
P = 0.64 and rs1554286, P = 0.54], IL10RA SNPs [rs2256111, P = 
0.18; rs4252243, P = 1.00; and rs2228054, P = 0.51], and IL10RB 
SNPs [rs999788, P = 0.49 and rs2834167, P = 0.34]). Genotype 
distributions of seven SNPs for control and BPH subjects are 
analyzed. There were no associations between control and BPH 
subjects, maybe, due to high prevalence in Korean population 
(IL10 SNPs [rs1518111, P = 0.70 and rs1554286, P = 0.69], IL10RA 
SNPs [rs2256111, P = 0.91; rs4252243, P = 0.26; and rs2228054, P 
= 0.83], and IL10RB SNPs [rs999788, P = 0.22 and rs2834167, P = 
0.80]). The genotype distributions of seven SNPs were analyzed 
according to low (0-19) and high (≥ 20) IPSS scores. No signifi-
cant associations were found between IPSS score (IL10 SNPs 
[rs1518111, P = 0.64 and rs1554286, P = 0.54], IL10RA SNPs 
[rs2256111, P = 0.18; rs4252243, P = 1.00; and rs2228054, P = 
0.51], and IL10RB SNPs [rs999788, P = 0.49 and rs2834167, P = 
0.34]). In allele analysis, there were no significant differences 
according to IPSS score. Table 3 shows genotype distributions 
of seven SNPs for low (< 1.5 ng/mL) and high (≥ 1.5 ng/mL) PSA 
level. The T/T genotype of IL10RB polymorphism (rs999788) 
was associated with a high PSA level compared with the T/C + 
C/C genotypes (95% CI 0.28-0.95, P = 0.031). Moreover, the G/G 
genotype of IL10RB polymorphism (rs2834167) was associated 
with a high PSA level compared with the A/G + A/A genotypes 
(95% CI 0.23-0.83, P = 0.009). In allele analysis, however, there 
were no significant differences. The genotype distributions of 
SNPs were analyzed according to low (< 10 mL/sec) and high  
(≥ 10 mL/sec) Qmax. There were no significant associations be-
tween low and high Qmax. In allele analysis, there were no signif-
icant differences according to Qmax.
  There were significant associations between IL10 and IL10RB 
SNPs, and prostatic volume in Table 4. Of IL10 SNP, rs1518111 
(95% CI 1.01-2.31, P = 0.044 in codominant model, 95% CI 1.17-
3.34, P = 0.011 in dominant model) and rs1554286 (95% CI 1.00-
2.30, P = 0.047 in codominant model, 95% CI 1.16-3.32, P = 0.014 
in dominant model) were associated with prostatic volume. The 
G allele of rs1518111 and the C allele of rs1554286 were found 
to be significantly associated with large prostatic volume and a 
Table 3. Analysis of genotype frequencies in IL10, IL10RA, and IL10RB gene polymorphisms, based on low (< 1.5 ng/mL) and high (≥ 1.5 ng/mL) PSA level, in subjects with BPH
SNP (Locus) Genotype
Low PSA High PSA
Model OR (95% CI) P
n = 86 (%) n = 146 (%)
IL10
   rs1518111
      Intron
   rs1554286
      Intron
A/A
A/G
G/G
T/T
T/C
C/C
45 (52.3)
31 (36.0)
10 (11.6)
43 (50.0)
33 (38.4)
10 (11.6)
61 (41.8)
74 (50.7)
11 (7.5)
61 (41.8)
74 (50.7)
11 (7.5)
Codominant
Dominant
Recessive
Codominant
Dominant
Recessive
1.17 (0.77-1.78)
1.53 (0.89-2.61)
0.62 (0.25-1.53)
1.11 (0.73-1.68)
1.39 (0.82-2.38)
0.62 (0.25-1.53)
0.46
0.12
0.30
0.64
0.22
0.30
IL10RA
   rs2256111
   Ala153Ala
   rs4252243
   -1379C>T
   rs2228054
   Pro175Pro
G/G
A/G
A/A
C/C
T/C
T/T
G/G
A/G
A/A
36 (41.9)
40 (46.5)
10 (11.6)
74 (86.0)
10 (11.6)
2 (2.3)
43 (50.0)
37 (43.0)
6 (7.0)
59 (40.4)
70 (48.0)
17 (11.6)
113 (77.4)
33 (22.6)
0 (0)
69 (47.3)
68 (46.6)
9 (6.2)
Codominant
Dominant
Recessive
Codominant
Dominant
Recessive
Codominant
Dominant
Recessive
1.03 (0.69-1.55)
1.06 (0.62-1.82)
1.00 (0.44-2.30)
1.45 (0.75-2.81)
1.80 (0.87-3.71)
0.00 (0.00-NA)
1.05 (0.68-1.63)
1.12 (0.65-1.90)
0.88 (0.30-2.55)
0.87
0.83
1.00
0.26
0.10
0.82
0.69
0.81
IL10RB
   rs999788
   -641T>C
   rs2834167
   Lys47Glu
T/T
T/C
C/C
G/G
A/G
A/A
19 (22.1)
48 (55.8)
19 (22.1)
16 (18.6)
51 (59.3)
19 (22.1)
51 (35.4)
65 (45.1)
28 (19.4)
50 (34.2)
66 (45.2)
30 (20.6)
Codominant
Dominant
Recessive
Codominant
Dominant
Recessive
0.72 (0.49-1.06)
0.52 (0.28-0.95)
0.85 (0.44-1.64)
0.70 (0.48-1.03)
0.44 (0.23-0.83)
0.91 (0.48-1.74)
0.097
0.031
0.63
0.07
0.009
0.78
BPH, benign prostatic hyperplasia; CI, confidence interval; IL10, interleukin-10; IL10RA, interleukin-10 receptor, alpha; IL10RB, interleukin-10 receptor, beta; OR, odds ratio; 
PSA, prostate-specific antigen; SNP, single nucleotide polymorphism.
Table 2. The clinical characteristics of 233 BPH patients
Parameters  Mean ± SE
Age (yr) 65.85 ± 0.60
IPSS 17.71 ± 0.54
QoL 3.57 ± 0.09
PSA (ng/mL) 4.43 ± 0.35
Free PSA (ng/mL) 0.98 ± 0.08
Qmax (mL/sec) 11.34 ± 0.38
Qavg (mL/sec) 6.49 ± 0.25
VV (mL) 209.10 ± 12.11
PVR (mL) 60.09 ± 6.81
Total prostate volume (mL) 38.97 ± 1.39
Inner prostate volume (mL) 18.13 ± 1.23
BPH, benign prostatic hyperplasia; IPSS, international prostate symptom score; QoL, 
quality of life; PSA, prostate-specific antigen; Qmax, peak urinary flow rate; Qavg, average 
urinary flow rate; VV, voided volume; PVR, postvoid residual urine.Yoo KH, et al.  •  Polymorphism of IL10, IL10RA, and IL10RB in Benign Prostatic Hyperplasia
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risk factor for increased prostatic volume in present study. More-
over, the T/T genotype of IL10RB polymorphism (rs999788) was 
associated with high prostatic volume compared with the T/C 
+ C/C genotypes (95% CI 0.30-0.96, P = 0.033). In allele analysis, 
however, there were no significant differences according to pros-
tatic volume.
  Seven SNPs were analyzed for LD and haplotypes using Hap-
loview (version 4.2) according to IPSS score, serum PSA level, 
Qmax, and prostatic volume. The LD blocks were formed in IL10 
and IL10RA (Fig. 2). The LD block of IL10 gene consisted of 
rs1554286 and rs1518111. The LD block of IL10RA gene con-
sisted of rs2256111 and rs2228054. However, haplotypes in the 
LD block of IL10 and IL10RA were not associated within BPH 
subjects based on prostatic volume (Table 5).
DISCUSSION
Cytokines play multiple roles in both immune disorders and 
Fig. 2. Linkage disequilibrium (LD) blocks are consisted in IL10 (A) and IL10RA (B). 
LD block in IL10RB (C) is not consisted. IL10, interleukin-10; IL10RA, interleukin-10 
receptor, alpha; IL10RB, interleukin-10 receptor, beta.
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Table 4. Analysis of genotype frequencies in IL10, IL10RA, and IL10RB gene polymorphisms, based on small (< 30 mL) and large (≥ 30 mL) prostatic volume, in subjects with BPH
SNP (Locus) Genotype
Small volume Large volume
Model OR (95% CI) P
n = 101 (%) n = 132 (%)
IL10
   rs1518111
      Intron
 
   rs1554286
      Intron
 
A/A
A/G
G/G
T/T
T/C
C/C
56 (55.5)
36 (35.6)
9 (8.9)
55 (54.5)
37 (36.6)
9 (8.9)
51 (38.6)
69 (52.3)
12 (9.1)
50 (37.9)
70 (53.0)
12 (9.1)
Codominant
Dominant
Recessive
Codominant
Dominant
Recessive
1.52 (1.01-2.31)
1.98 (1.17-3.34)
1.02 (0.41-2.53)
1.52 (1.00-2.30)
1.96 (1.16-3.32)
1.02 (0.41-2.53)
0.044
0.011
0.96
0.047
0.014
0.96
IL10RA
   rs2256111
   Ala153Ala
 
   rs4252243
   -1379C>T
 
   rs2228054
   Pro175Pro
 
G/G
A/G
A/A
C/C
T/C
T/T
G/G
A/G
A/A
38 (37.6)
55 (54.5)
8 (7.9)
86 (85.2)
14 (13.9)
1 (1.0)
46 (45.5)
50 (49.5)
5 (5.0)
57 (43.2)
56 (42.4)
19 (14.4)
102 (77.3)
29 (22.0)
1 (0.8)
66 (50.0)
56 (42.4)
10 (7.6)
Codominant
Dominant
Recessive
Codominant
Dominant
Recessive
Codominant
Dominant
Recessive
1.02 (0.69-1.51)
0.79 (0.47-1.35)
1.95 (0.82-4.67)
1.56 (0.82-2.96)
1.69 (0.85-3.34)
0.76 (0.05-12.35)
0.95 (0.62-1.46)
0.84 (0.50-1.41)
1.57 (0.52-4.76)
0.92
0.39
0.12
0.17
0.13
0.85
0.82
0.50
0.41
IL10RB
   rs999788
   -641T>C
 
   rs2834167
   Lys47Glu
 
T/T
T/C
C/C
G/G
A/G
A/A
23 (23.0)
55 (55.0)
22 (22.0)
22 (21.8)
56 (55.5)
23 (22.8)
47 (35.9)
59 (45.0)
25 (19.1)
44 (33.3)
62 (47.0)
26 (19.7)
Codominant
Dominant
Recessive
Codominant
Dominant
Recessive
0.73 (0.50-1.05)
0.53 (0.30-0.96)
0.84 (0.44-1.59)
0.74 (0.51-1.08)
0.56 (0.31-1.01)
0.83 (0.44-1.57)
0.091
0.033
0.59
0.11
0.05
0.57
BPH, benign prostatic hyperplasia; CI, confidence interval; IL10, interleukin-10; IL10RA, interleukin-10 receptor, alpha; IL10RB, interleukin-10 receptor, beta; OR, odds ratio; 
SNP, single nucleotide polymorphism.
Table 5. Haplotypes in the linkage disequilibrium (LD) block of IL10 and IL10RA based on small (< 30 mL) and large (≥ 30 mL) prostatic volume, in subjects with BPH
Gene Block Haplotype Frequency
Small volume Large volume
  Chi square P
+ - + -
IL10 Block 1 TA
CG
0.678
0.313
147
  54
  55
148
169
  92
  95
172
  4.021
  3.503
0.05
0.06
IL10RA Block 2 GG
AA
AG
0.646
0.292
0.062
131
  60
  11
  71
142
191
170
  76
  18
  94
188
246
0.01
  0.046
  0.369
0.92
0.83
0.54
IL10, interleukin-10; IL10RA, interleukin-10 receptor, alpha; IL10RB, interleukin-10 receptor, beta.
5
6 7Yoo KH, et al.  •  Polymorphism of IL10, IL10RA, and IL10RB in Benign Prostatic Hyperplasia
http://jkms.org   663 DOI: 10.3346/jkms.2011.26.5.659
many complex diseases. Inflammatory processes are strongly 
influenced by the balance between the effects of pro-inflamma-
tory and anti-inflammatory cytokines. Several cytokines have 
been suggested for their role in BPH (7). Cytokines are crucial 
regulators of cellular function and polymorphisms in cytokines 
related with BPH could be very important, not only for assess-
ing the risk of BPH but also in helping to explain the pathogen-
esis and progression of disease. 
  IL10 is a multifunctional cytokine with anti-inflammatory and 
anti-angiogenic properties (12-14). IL10 has been reported to 
reduce tumor growth and angiogenesis (15-17). IL10 mediates 
tumor promoting and tumor suppressive activities such as apop-
tosis (18). A large number of polymorphisms have been identi-
fied in the IL10 gene promoter (19). Low IL10 producing geno-
types were associated with increased susceptibility and advanced 
stage of several diseases such as malignant melanoma and re-
nal cell carcinoma. However, high IL10 producing genotypes 
were associated with poor outcome of cervical cancer, gastric 
cancer, and hepatocellular carcinoma (19). 
  Several studies were reported in IL10 polymorphism related 
with prostate cancer and BPH (18, 20-24). Two of these studies 
found significant results. McCarron et al. (20) reported a signifi-
cant association of the homozygous variant at -1082 with pros-
tate cancer risk. Both the A/G and A/A genotype at -1082 have 
been associated with low IL10 production. The T allele at the 
-819 has been associated with low IL10 production. They con-
cluded that SNP associated with differential production of IL10 
are risk factor for prostate cancer acting via their influence on 
angiogenesis. Faupel-Badger et al. (24) examined the hypothe-
sis that genotypes correlated with low IL10 production may be 
associated with increased prostate cancer risk among Finnish 
male participants from the Alpha-tocopherol Beta-carotene 
Cancer Prevention Study. The -819 T/T and -592 A/A low expres-
sion genotypes were highly correlated. These two genotypes also 
were associated with increased prostate cancer susceptibility 
and high grade tumors. These data revealed that genotypes cor-
related with low IL10 production are associated with increased 
risk of prostate cancer and with high-grade disease in Finnish 
male (24). Mullan et al. (18) reported the associations between 
BPH and polymorphism in genes that encode growth factor, 
cytokines, and vitamin D and receptor. The C/C genotype of the 
transforming growth factor-beta 1 gene was inversely associat-
ed with treatment for BPH. The presence of at least one allele 
with 17 or more CA repeats of the epidermal growth factor re-
ceptor gene was positively associated with high IPSS score. How-
ever, IL10 SNP (rs1800896) was not significantly associated with 
BPH.  
  In our study, G/G genotype of rs2834167 had a significant as-
sociation with high PSA level. Moreover, the G allele of rs1518111 
and the C allele of rs1554286 were found to be significantly as-
sociated with large prostate volume. We suggest that IL10 may 
be linked to reduce tumor growth and angiogenesis. He et al. (6) 
reported that the IL10 levels of expressed prostate secretion were 
higher in type II and type IIIa chronic prostatitis patients than 
in controls. They concluded that IL10 presumably play an im-
portant role in the process of prostate inflammation. 
  The limitation of our study was small sample number used 
for comparison within BPH group. But we have performed the 
first genetic examination of the relationships between IL10, IL-
10RA and IL10RB SNPs, and BPH, using standard diagnostic tools. 
Our results revealed a strong association between rs1518111, 
rs1554286, rs999788, and rs2834167 SNPs and BPH.
  In conclusion, there is a strong association between the IL10 
SNPs (rs1518111, rs1554286) and IL10RB SNPs (rs999788, 
rs2834167), and BPH in Korean population. Although our re-
sults have confirmed an association of IL10 and IL10RB SNP 
and BPH, additional investigation is needed for understanding 
protein expression in BPH.
REFERENCES
1. Park HK, Park H, Cho SY, Bae J, Jeong SJ, Hong SK, Yoon CY, Byun SS, 
Lee SE, Kim KW. The prevalence of benign prostatic hyperplasia in el-
derly men in Korea: a community-based study. Korean J Urol 2009; 50: 
843-7.
2. Kramer G, Mitteregger D, Marberger M. Is benign prostatic hyperplasia 
(BPH) an immune inflammatory disease? Eur Urol 2007; 51: 1202-16.
3. Konwar R, Gara R, Singh M, Singh V, Chattopadhyay N, Bid HK. Associ-
ation of interleukin-4 and interleukin-1 receptor antagonist gene poly-
morphisms and risk of benign prostatic hyperplasia. Urology 2008; 71: 
868-72.
4. Robinette CL. Sex-hormone-induced inflammation and fibromuscular 
proliferation in the rat lateral prostate. Prostate 1988; 12: 271-86.
5. Kramer G, Steiner GE, Handisurya A, Stix U, Haitel A, Knerer B, Gessl A, 
Lee C, Marberger M. Increased expression of lymphocyte-derived cyto-
kines in benign hyperplastic prostate tissue, identification of the produc-
ing cell types, and effect of differentially expressed cytokines on stromal 
cell proliferation. Prostate 2002; 52: 43-58.
6. He L, Wang Y, Long Z, Jiang C. Clinical significance of IL-2, IL-10, and 
TNF-alpha in prostatic secretion of patients with chronic prostatitis. Urol-
ogy 2010; 75: 654-7.
7. Konwar R, Chattopadhyay N, Bid HK. Genetic polymorphism and patho-
genesis of benign prostatic hyperplasia. BJU Int 2008; 102: 536-44.
8. Kaplan SA, McConnell JD, Roehrborn CG, Meehan AG, Lee MW, Noble 
WR, Kusek JW, Nyberg LM Jr; Medical Therapy of Prostatic Symptoms 
(MTOPS) Research Group. Combination therapy with doxazosin and 
finasteride for benign prostatic hyperplasia in patients with lower urinary 
tract symptoms and a baseline total prostate volume of 25 ml or greater. 
J Urol 2006; 175: 217-20.
9. Siami P, Roehrborn CG, Barkin J, Damiao R, Wyczolkowski M, Duggan 
A, Major-Walker K, Morrill BB; CombAT study group. Combination ther-
apy with dutasteride and tamsulosin in men with moderate-to-severe 
benign prostatic hyperplasia and prostate enlargement: the CombAT 
(Combination of Avodart and Tamsulosin) trial rationale and study de-Yoo KH, et al.  •  Polymorphism of IL10, IL10RA, and IL10RB in Benign Prostatic Hyperplasia
664   http://jkms.org DOI: 10.3346/jkms.2011.26.5.659
sign. Contemp Clin Trials 2007; 28: 770-9.
10. Lewis CM. Genetic association studies: design, analysis and interpreta-
tion. Brief Bioinform 2002; 3: 146-53.
11. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualiza-
tion of LD and haplotype maps. Bioinformatics 2005; 21: 263-5.
12. Bagnoli S, Cellini E, Tedde A, Nacmias B, Piacentini S, Bessi V, Bracco L, 
Sorbi S. Association of IL10 promoter polymorphism in Italian Alzheim-
er’s disease. Neurosci Lett 2007; 418: 262-5.
13. Deans DA, Tan BH, Ross JA, Rose-Zerilli M, Wigmore SJ, Howell WM, 
Grimble RF, Fearon KC. Cancer cachexia is associated with the IL10 -1082 
gene promoter polymorphism in patients with gastroesophageal malig-
nancy. Am J Clin Nutr 2009; 89: 1164-72.
14. Heiskanen M, Kähönen M, Hurme M, Lehtimäki T, Mononen N, Juonala 
M, Hutri-Kähönen N, Viikari J, Raitakari O, Hulkkonen J. Polymorphism 
in the IL10 promoter region and early markers of atherosclerosis: the Car-
diovascular Risk in Young Finns Study. Atherosclerosis 2010; 208: 190-6.
15. Huang S, Xie K, Bucana CD, Ullrich SE, Bar-Eli M. Interleukin 10 sup-
presses tumor growth and metastasis of human melanoma cells: poten-
tial inhibition of angiogenesis. Clin Cancer Res 1996; 2: 1969-79.
16. Kundu N, Beaty TL, Jackson MJ, Fulton AM. Antimetastatic and antitu-
mor activities of interleukin 10 in a murine model of breast cancer. J Natl 
Cancer Inst 1996; 88: 536-41.
17. Stearns ME, Rhim J, Wang M. Interleukin 10 (IL-10) inhibition of prima-
ry human prostate cell-induced angiogenesis: IL-10 stimulation of tissue 
inhibitor of metalloproteinase-1 and inhibition of matrix metalloprotein-
ase (MMP)-2/MMP-9 secretion. Clin Cancer Res 1999; 5: 189-96.
18. Mullan RJ, Bergstralh EJ, Farmer SA, Jacobson DJ, Hebbring SJ, Cunning-
ham JM, Thibodeau SN, Lieber MM, Jacobsen SJ, Roberts RO. Growth 
factor, cytokine, and vitamin D receptor polymorphisms and risk of be-
nign prostatic hyperplasia in a community-based cohort of men. Urolo-
gy 2006; 67: 300-5.
19. Howell WM, Rose-Zerilli MJ. Interleukin-10 polymorphisms, cancer sus-
ceptibility and prognosis. Fam Cancer 2006; 5: 143-9.
20. McCarron SL, Edwards S, Evans PR, Gibbs R, Dearnaley DP, Dowe A, 
Southgate C, Easton DF, Eeles RA, Howell WM. Influence of cytokine 
gene polymorphisms on the development of prostate cancer. Cancer Res 
2002; 62: 3369-72.
21. Eder T, Mayer R, Langsenlehner U, Renner W, Krippl P, Wascher TC, 
Pummer K, Kapp KS. Interleukin-10 [ATA] promoter haplotype and pros-
tate cancer risk: a population-based study. Eur J Cancer 2007; 43: 472-5.
22. Xu J, Lowey J, Wiklund F, Sun J, Lindmark F, Hsu FC, Dimitrov L, Chang 
B, Turner AR, Liu W, Adami HO, Suh E, Moore JH, Zheng SL, Isaacs WB, 
Trent JM, Grönberg H. The interaction of four genes in the inflammation 
pathway significantly predicts prostate cancer risk. Cancer Epidemiol 
Biomarkers Prev 2005; 14(11 Pt 1): 2563-8.
23. Michaud DS, Daugherty SE, Berndt SI, Platz EA, Yeager M, Crawford 
ED, Hsing A, Huang WY, Hayes RB. Genetic polymorphisms of interleu-
kin-1B (IL-1B), IL-6, IL-8, and IL-10 and risk of prostate cancer. Cancer 
Res 2006; 66: 4525-30.
24. Faupel-Badger JM, Kidd LC, Albanes D, Virtamo J, Woodson K, Tangrea 
JA. Association of IL-10 polymorphisms with prostate cancer risk and 
grade of disease. Cancer Causes Control 2008; 19: 119-24.
AUTHOR SUMMARY
Association of IL10, IL10RA, and IL10RB Polymorphisms with Benign Prostate 
Hyperplasia in Korean Population
Koo Han Yoo, Su Kang Kim, Joo-Ho Chung, and Sung-Goo Chang
Inflammation has been documented in benign prostatic hyperplasia (BPH). Cytokines such as interleukin 10 (IL10) may play an 
important role in the process of inflammation. Therefore we analyzed the association between the BPH and single nucleotide 
polymorphisms (SNPs) of IL10, IL10RA and IL10RB in Korean population (233 BPH subjects and 214 age-matched healthy subjects). 
All patients with BPH were divided into two groups according to IPSS, PSA level, Qmax, and prostate volume. Genotypes of seven 
SNPs were determined through direct sequencing. The T/T genotype of rs999788 and the G/G genotype of rs2834167 were 
associated with a high PSA level. Of IL10 SNP, the A/A genotype of rs1518111 and the T/T genotype of rs1554286 were associated 
with small prostatic volume. Moreover, the T/T genotype of rs999788 was associated with high prostatic volume. We conclude 
that there is a strong association between the IL10 and IL10RB SNPs, and BPH in Korean population.